Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Caamtech Inc. manages a company patent portfolio that currently includes 8 pending office actions within the Biotechnology & Pharmaceuticals technology area. This substantial volume of active prosecution is spread across 6 distinct art units, indicating that the company's research and development efforts cover a wide range of biological and pharmaceutical sub-specialties. Navigating 6 distinct art units requires a sophisticated strategy to address the varying examination standards in each unit.
The 8 pending office actions are being reviewed by 8 distinct examiners, creating a 1 to 1 ratio between active cases and examiners. This ensures that no single examiner is managing more than one application for the company, which may lead to a broader range of examiner feedback. ANDERSON, JAMES D is the busiest examiner for Caamtech Inc., currently responsible for 1 pending office action.
With 8 pending office actions and 8 distinct examiners, the portfolio's prosecution is highly decentralized. The 6 distinct art units involved further emphasize the technical breadth of the company's filings in the Biotechnology & Pharmaceuticals sector. ANDERSON, JAMES D, as the busiest examiner with 1 pending action, is part of a large group of examiners currently evaluating Caamtech Inc.'s intellectual property.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (38%) |
| §102 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON, JAMES D | 1 | 55.1% | +19.3% |
| OH, TAYLOR V | 1 | 81.2% | +15.3% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
| CHICKS, ASHLI ARIANA | 1 | 60.6% | +50.3% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18898755 | CRYSTALLINE 5-METHOXY-DIPROPYL TRYPTAMINE COMPOUNDS | OH, TAYLOR V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352677 | COMPOSITIONS CONTAINING KRATOM COMPOUNDS | SPAINE, ROBERT FRANKLIN | 441d overdue |
| 18858080 | CRYSTALLINE QUATERNARY SALTS OF 4-SUBSTITUTED TRYPTAMINES | ANDERSON, JAMES D | 44d overdue |
| 17495069 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | CORNET, JEAN P | 54d |
| 17627988 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | NOTTINGHAM, KYLE GREGORY | — |
| 17620855 | IBOGAINE FORMULATIONS | PECKHAM, RICHARD GRANT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18858080 | CRYSTALLINE QUATERNARY SALTS OF 4-SUBSTITUTED TRYPTAMINES | ANDERSON, JAMES D | 44d overdue |
| 17495069 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | CORNET, JEAN P | 54d |
| 18898755 | CRYSTALLINE 5-METHOXY-DIPROPYL TRYPTAMINE COMPOUNDS | OH, TAYLOR V | — |
| 18260711 | PROTECTED ALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | CHICKS, ASHLI ARIANA | — |
| 17627988 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | NOTTINGHAM, KYLE GREGORY | — |
| 17620855 | IBOGAINE FORMULATIONS | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1655 | 1 |
| 1626 | 1 |
| 1621 | 1 |
| 1627 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858080 | CRYSTALLINE QUATERNARY SALTS OF 4-SUBSTITUTED TRYPTAMINES | ANDERSON, JAMES D | 1629 | §102§112 | Non-Final OA | 44d overdue | Pending | Oct 18, 2024 |
| 18898755 | CRYSTALLINE 5-METHOXY-DIPROPYL TRYPTAMINE COMPOUNDS | OH, TAYLOR V | — | §103§112DP | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18781180 | CRYSTALLINE BIS-MIPROCIN FUMARATE | JACKSON, SHAWQUIA | — | §112DP | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18352677 | COMPOSITIONS CONTAINING KRATOM COMPOUNDS | SPAINE, ROBERT FRANKLIN | 1655 | §101§103Other | Non-Final OA | 441d overdue | Pending | Jul 14, 2023 |
| 18260711 | PROTECTED ALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | CHICKS, ASHLI ARIANA | 1626 | §102Other | Non-Final OA | — | Pending | Jul 07, 2023 |
| 17627988 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | NOTTINGHAM, KYLE GREGORY | 1621 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 18, 2022 |
| 17620855 | IBOGAINE FORMULATIONS | PECKHAM, RICHARD GRANT | 1627 | §101§103 | Final Rejection | — | Pending | Dec 20, 2021 |
| 17495069 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | CORNET, JEAN P | 1628 | §103§112Other | Non-Final OA | 54d | Pending | Oct 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial